Dr. Harry Andrew Mayer, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 28 Sturdy St, Attleboro, MA 02703 Phone: 508-226-5681 Fax: 508-226-5886 |
Daniel Carter Brown, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 562 Washington St, Attleboro, MA 02703 Phone: 508-761-5650 Fax: 508-761-9870 |
Dr. Polyxeni Gudis, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-222-5200 Fax: 508-023-6733 |
Mr. David Eferoghene Ukpokpo, MSN, APRN, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 410 Read St, Attleboro, MA 02703 Phone: 617-792-7612 |
Dr. Gary M Cummins, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 401-864-2741 |
News Archive
A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.
The findings, which come from a Journal of Diabetes analysis of 11,515 men and 13,569 women in China, indicate that nutrition in early life may play a role in the development of subsequent metabolic disorders.
Exposure to environments outside a comfortable temperature could help tackle major metabolic diseases, such as diabetes and obesity, and should be reflected in modern building practices, finds a study published today.
The longstanding ethical framework for protecting human volunteers in medical research needs to be replaced because it is outdated and can impede efforts to improve health care quality, assert leaders in bioethics, medicine, and health policy in two companion articles in a Hastings Center Report special report, "Ethical Oversight of Learning Health Care Systems."
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 6 days ago